Roche Diagnostics India gets import licence for COVID-19 antibody test kit from CDSCO

Image
Press Trust of India New Delhi
Last Updated : May 07 2020 | 7:30 PM IST

Roche Diagnostics India on Thursday said it has received import licence from the Central Drugs Standard Control Organisation (CDSCO) for its Elecsys Anti-SARS-CoV-2 test kit and is readying to bring it to India.

The import licence has been issued by the drug regulator due to the emergency health situation in public interest, Roche Diagnostics India said in a statement.

"From bringing the globally used tests to the country in record time to establishing the disease control measures by creating COVID-19 diagnostic hubs..., the Indian government and the state governments have been collaborating with various sections of the healthcare system to manage the situation," Roche Diagnostics India MD Shravan Subramanyam said.

Laboratory-based immunodiagnostic testing will complement the existing reverse transcription polymerase chain reaction (RT-PCR) solutions to possibly ascertain coronavirus-related immunity among patients and all those who want to 'go back to work' to bring the health and economic activity back to normalcy, he added.

The test can support priority screening of high-risk groups, such as healthcare workers, delivery service providers, or food supply workers who might already have been exposed and developed an immune response, the statement said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 07 2020 | 7:30 PM IST

Next Story